Invitrogen plans to launch a new drug-screening platform early in the second quarter as a key part of its strategy to build its nascent screening-services business, company officials told BioCommerce Week.

The SelectScreen Profiling and Screening Services platform was initially launched in 2004 and builds off of the firm's kinase-screening business. The new platform — enabled by SSi Robotics' automation technology — will enable Invitrogen researchers to perform assays more quickly at higher throughput, the officials said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.